Results 201 to 210 of about 67,365 (299)

Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis

J Ambrose Martino, Alexander Oles, Brandon L. Rogalski, Josef K Eichinger, Richard J Friedman   +4 more
openalex   +2 more sources

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Biomimetic MCC950‐loaded cerium‐layered double hydroxide nanoparticles for targeted treatment of Type 1 diabetes in streptozotocin‐induced mice

British Journal of Pharmacology, EarlyView.
The CLMBM nanoparticle (NP) system demonstrates strong and targeted anti‐ROS, antiapoptotic and anti‐inflammatory properties within the pancreas, thereby inhibiting the onset and progression of type 1 diabetes. Background and Purpose The destruction of β‐cells in type 1 diabetes is driven by signalling cascades that ultimately lead to cell apoptosis ...
Huiwen Pang, Zhuo Chen, Youzhi Wu, Thanh‐Truc Nguyen, Jingjing Wang, David M. Klyne, Zhi Ping Xu, Chen Chen, Alan Rowan, Felicity Y. Han   +9 more
wiley   +1 more source

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study. [PDF]

ACR Open Rheumatol
Frier K, Dietl M, Aronson S, Dhani J, James K, Betensky D, Selzer F, Losina E, Katz JN, Kim JS, Weiss-Laxer NS.   +10 more
europepmc   +1 more source

Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

J Gen Intern Med
Rashid Z, Woldesenbet S, Khalil M, Altaf A, Zindani S, Mevawalla A, Sarfraz A, Mumtaz K, Pawlik TM.   +8 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Distribution of glucagon-like peptide 1 receptor and insulin in phaeochromocytomas. [PDF]

Endocr Connect
Følling I, Selle ML, Nilsen HR, Wennerström AB, Nilsen HL, Eide TJ.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: A New Era in Cardiometabolic and Cardiovascular Care

Masih Tajdini
openalex   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes. [PDF]

J Clin Med
Žaliukaitė G, Lebbar N.
europepmc   +1 more source